Dabigatran: Ready for prime time?

Polskie Archiwum Medycyny Wewnetrznej

Volumn 120, Issue 4, 2010, Pages 137-142

  Karthikeyan, Ganesan ^a   Eikelboom, John W ^b   Hirsh, Jack ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Atrial fibrillation; Dabigatran; Thrombin inhibitors; Venous thromboembolism

Indexed keywords

AMIODARONE; APIXABAN; DABIGATRAN ETEXILATE; ENOXAPARIN; PLACEBO; QUINIDINE; RIVAROXABAN; VERAPAMIL; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; BLOOD LEVEL; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DYSPEPSIA; EMBOLISM; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LONG TERM CARE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; STROKE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 77952794745     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.909     Document Type: Review

References (13)

1. Karthikeyan G, Eikelboom JW, Hirsh J. New oral anticoagulants: not quite there yet. Pol Arch Med Wewn. 2009; 119:53-58.
2. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139-1151.
3. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361:2342-2352.
4. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008; 36:386-399. (Pubitemid 351185753)
5. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007; 64: 292-303. (Pubitemid 47283865)
6. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood. 2009: blood-2009-09-241851.
7. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999; 131: 492-501. (Pubitemid 29482392)
8. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005; 3: 692-694. (Pubitemid 41647882)
9. Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI46): a randomised, double-blind, phase II trial. Lancet. 2009; 374: 29-38.
10. Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009; 119: 2877-2885.
11. Eriksson BI, Kakkar AK, Turpie AG, et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br. 2009; 91: 636-644.
12. Lassen MR, Raskob GE, Gate A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009; 361: 594-604.
13. Lassen MR, Raskob GE, Gate A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807-815.